$163,082,416
to ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on a 2022 contract to manufacture Sabin's Sudan Ebolavirus vaccine in bulk for outbreak response.
Ensures U.S. capacity to rapidly deploy Ebola vaccines during public health emergencies; part of HHS pandemic preparedness infrastructure.
Signals sustained federal investment in domestic vaccine manufacturing capacity and cold-chain readiness for emerging infectious diseases.
Reflects U.S. commitment to independent vaccine production capability rather than reliance on foreign suppliers during health crises.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-23. Cost: $0.002965.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50123C00010_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.